Donald A. Bergstrom M.D., Ph.D.
Net Worth

Last updated:

What is Donald A. Bergstrom M.D., Ph.D. net worth?

The estimated net worth of Dr. Donald A. Bergstrom M.D., Ph.D. is at least $12,295,707 as of 27 Jun 2024. He owns shares worth $1,791,049 as insider, has earned $7,825,378 from insider trading and has received compensation worth at least $2,679,280 in Relay Therapeutics, Inc..

What is the salary of Donald A. Bergstrom M.D., Ph.D.?

Dr. Donald A. Bergstrom M.D., Ph.D. salary is $669,820 per year as Executive Vice President and Head of R&D in Relay Therapeutics, Inc..

How old is Donald A. Bergstrom M.D., Ph.D.?

Dr. Donald A. Bergstrom M.D., Ph.D. is 53 years old, born in 1972.

What stocks does Donald A. Bergstrom M.D., Ph.D. currently own?

As insider, Dr. Donald A. Bergstrom M.D., Ph.D. owns shares in one company:

Company Title Shares Price per share Total value
Relay Therapeutics, Inc. (RLAY) Executive Vice President and Head of R&D 526,779 $3.4 $1,791,049

What does Relay Therapeutics, Inc. do?

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Donald A. Bergstrom M.D., Ph.D. insider trading

Relay Therapeutics, Inc.

Dr. Donald A. Bergstrom M.D., Ph.D. has made 42 insider trades between 2021-2024, according to the Form 4 filled with the SEC. Most recently he sold 648 units of RLAY stock worth $4,056 on 27 Jun 2024.

The largest trade he's ever made was exercising 56,324 units of RLAY stock on 16 Apr 2021. As of 27 Jun 2024 he still owns at least 526,779 units of RLAY stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 648 $6.26 $4,056
Sale
Common Stock 2,686 $6.38 $17,137
Sale
Common Stock 765 $7.7 $5,891
Sale
Common Stock 3,178 $9.64 $30,636
Sale
Common Stock 977 $11.51 $11,245
Sale
Common Stock 3,451 $6.03 $20,810
Sale
Common Stock 648 $8.38 $5,430
Sale
Common Stock 2,683 $11.8 $31,659
Sale
Common Stock 647 $12.12 $7,842
Sale
Common Stock 1,383 $11.16 $15,434
Sale
Common Stock 763 $15.36 $11,720
Sale
Common Stock 1,429 $21.56 $30,809
Sale
Common Stock 980 $14.49 $14,200
Sale
Common Stock 8,000 $22.75 $182,000
Option
Common Stock 8,000 $4.12 $32,960
Option
Stock Option (Right to Buy) 8,000 $4.12 $32,960
Sale
Common Stock 1,817 $21.54 $39,138
Sale
Common Stock 8,000 $22.43 $179,440
Option
Stock Option (Right to Buy) 8,000 $4.12 $32,960
Option
Common Stock 8,000 $4.12 $32,960
Sale
Common Stock 976 $22.73 $22,184
Sale
Common Stock 25,000 $30 $750,000
Option
Common Stock 25,000 $4.12 $103,000
Option
Stock Option (Right to Buy) 25,000 $4.12 $103,000
Sale
Common Stock 4,900 $25.46 $124,754
Option
Stock Option (Right to Buy) 4,900 $4.12 $20,188
Option
Common Stock 4,900 $4.12 $20,188
Option
Common Stock 8,100 $4.12 $33,372
Sale
Common Stock 8,100 $23.07 $186,867
Option
Stock Option (Right to Buy) 8,100 $4.12 $33,372
Option
Stock Option (Right to Buy) 15,000 $4.12 $61,800
Option
Common Stock 15,000 $4.12 $61,800
Sale
Common Stock 15,000 $25 $375,000
Option
Stock Option (Right to Buy) 8,000 $4.12 $32,960
Sale
Common Stock 8,000 $20 $160,000
Option
Common Stock 8,000 $4.12 $32,960
Sale
Common Stock 1,835 $21.27 $39,030
Option
Common Stock 8,000 $4.12 $32,960
Option
Stock Option (Right to Buy) 8,000 $4.12 $32,960
Sale
Common Stock 8,000 $20 $160,000
Sale
Common Stock 999 $20.31 $20,290
Option
Stock Option (Right to Buy) 8,000 $4.12 $32,960
Option
Common Stock 8,000 $4.12 $32,960
Sale
Common Stock 8,000 $20 $160,000
Option
Common Stock 13,000 $4.12 $53,560
Option
Stock Option (Right to Buy) 13,000 $4.12 $53,560
Sale
Common Stock 13,000 $24.62 $320,060
Sale
Common Stock 1,811 $25.57 $46,307
Option
Stock Option (Right to Buy) 18,000 $4.12 $74,160
Sale
Common Stock 18,000 $30.32 $545,760
Option
Common Stock 18,000 $4.12 $74,160
Sale
Common Stock 622 $29.87 $18,579
Sale
Common Stock 10,000 $30 $300,000
Option
Common Stock 10,000 $4.12 $41,200
Option
Stock Option (Right to Buy) 10,000 $4.12 $41,200
Option
Stock Option (Right to Buy) 10,000 $4.12 $41,200
Option
Common Stock 10,000 $4.12 $41,200
Sale
Common Stock 10,000 $25 $250,000
Option
Common Stock 8,000 $4.12 $32,960
Option
Stock Option (Right to Buy) 8,000 $4.12 $32,960
Sale
Common Stock 8,000 $23.88 $191,040
Sale
Common Stock 8,000 $20.94 $167,520
Option
Stock Option (Right to Buy) 8,000 $4.12 $32,960
Option
Common Stock 8,000 $4.12 $32,960
Sale
Common Stock 2,752 $20.97 $57,709
Sale
Common Stock 12,242 $20.94 $256,347
Sale
Common Stock 649 $33.1 $21,482
Sale
Common Stock 30,000 $34.15 $1,024,500
Sale
Common Stock 646 $36.87 $23,818
Sale
Common Stock 976 N/A N/A
Option
Common Stock 42,242 $4.12 $174,037
Sale
Common Stock 42,242 $4.12 $174,037
Option
Stock Option (Right to Buy) 42,242 $4.12 $174,037
Sale
Common Stock 56,324 $32.36 $1,822,645

Relay Therapeutics key executives

Relay Therapeutics, Inc. executives and other stock owners filed with the SEC: